New gene therapy treatment for haemophilia B

View source ↗

Summary

The EMA announced that the gene therapy Durveqtix for haemophilia B has received PRIME designation to support its development and potential to improve patients'…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Durveqtix

Snippet

Durveqtix received support through the PRIority Medicines (PRIME) scheme due to its potential to improve patients’ quality of life